Beth N. McLellan, MD
- Practice Specialty
- Medical Education
- Wayne State University
- Henry Ford Hospital
- Main Location
- Academic Title
- Associate Professor, Dermatology
- Administrative Title
- Chief, Dermatology; Director, Supportive Oncodermatology
- Clinical Focus
- Dr. McLellan specializes in the treatment of skin, hair and nail conditions in cancer patients, with a special focus on reactions to new cancer drugs. She also cares for patients with skin cancer including nonmelanoma skin cancer, cutaneous lymphoma, and melanoma.
- Research Focus
- Dr. McLellan is currently investigating hair loss in breast cancer patients due to hormonal therapies such as tamoxifen and aromatase-inhibitors. Dr. McLellan’s research interests include chemotherapy-induced hair loss and nail problems, hand-foot syndrome and radiation dermatitis.
Scissors, B, Shwayder, T. Topical clindamycin reproducibly causing tinnitus in a 14-year-old male, Journal of the American Academy of Dermatology. 2006; 54(5 Suppl):S243-4.
Mossbridge JA, Scissors BN, Wright BA. Learning and generalization on asynchrony and order tasks at sound offset: Implications for underlying neural circuitry, Learning and Memory. 2008; 15:13-20.
Hornyak TJ, Giang S, Guzmán EA, Scissors BN, Tuchinda C, He H, Neville JD, Strickland FM. Mitf dosage as a primary determinant of melanocyte survival after ultraviolet irradiation. Pigment Cell Melanoma Research. 2009; 22:307-18.
McLellan B, Kerr HA. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatologic Therapy. 2011; 24:396-400.
McLellan B, Robert C, Lacouture ME. Dermatologic manifestations of skin cancer therapies. In Rigel: Cancer of the Skin 2nd ed. 2011.
McLellan B. How to recognize and manage hand-foot syndrome due to capecitabine or doxorubicin. The ASCO Post. 2013; 4.
Baum, S, Patel R, McLellan B. Clinicopathologic Challenge: A vascular growth following radiation therapy for breast carcinoma treatment. JAMA Dermatology. 2013; 149:1341-2.
Mir A, Boyd KP, Meehan SA, McLellan B. Hydroxychloroquine-induced hyperpigmentation. Dermatol Online J. 2013; 19:20723.
Eungdamrong J, McLellan B. Flagellate erythema. Dermatol Online J. 2013; 19:20716.
Terushkin V, Boyd KP, Patel RR, McLellan B. Primary localized cutaneous amyloidosis. Dermatol Online J. 2013; 19:20711.
Rose AE, Sagger V, Boyd KP, Patel RR, McLellan B. Livedo Reticularis. Dermatol Online J. 2013; 19:20705.
McLellan B, Patel D, Lacouture ME. Epidemiology and burden of disease. In Lacouture: Dermatological Practices and Principles in Oncology. 2013.
Miller K, Gorcey, L, McLellan BN. Chemotherapy-induced nail changes and hand-foot syndrome: A review of clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2014; 71:787-94.
Gorcey L, Lewin J, Meehan S, McLellan BN. Papular eruption associated with palifermin. J Am Acad Dermatol. 2014; 71:e101-2.
Bhardwaj AS, McLellan B, Robinson MR, Ghaw O, Lipsey LR, Tiersten AD, Morris GJ. A case of vasculitis in a breast cancer patient treated with T-DM1. Semin Oncol 2014; 41:e39-45.
Yost JM, Hale CS, Meehan SA, McLellan BN. Dermatitis herpetiformis. Dermatol Online J 2014; 20:13030.
Gumaste PV, Penn LA, Cymerman RM, Kirchhoff T, Polsky D, McLellan B. Skin cancer risk in BRCA1/2 mutation carriers. Br J Dermatol 2014; [Epub ahead of print]
Beth N. McLellan, MD, is Chief of the Division of Dermatology at Montefiore-Einstein, Director of Supportive Oncodermatology at Montefiore-Einstein Center for Cancer Care and Associate Professor of Dermatology at Albert Einstein College of Medicine. She is also Director of Dermatology at Jacobi Medical Center. She is committed to improving oncology patients’ quality of life and preventing interruptions in their care.
Prior to joining Montefiore, Dr. McLellan served as a full-time faculty member at New York University where she saw all inpatient dermatology consults and developed an oncodermatology program. Her medical training includes an internship in internal medicine at Loyola Medicine and dermatology residency at Henry Ford Health System in Detroit, where she served as chief resident and initiated a supportive oncodermatology clinic. Dr. McLellan received additional oncodermatology training at Memorial Sloan Kettering Cancer Center and at the Institute Gustave Roussy in Paris. She has received awards from the Women’s Dermatology Society and the Dermatology Foundation. She regularly lectures at both dermatology and oncology meetings and is actively involved in teaching medical students and residents.
As part of her commitment to treating the whole patient, Dr. McLellan founded the New York Vitiligo Support Group. You can get more information about this group by e-mailing firstname.lastname@example.org